StemCell Institute (TSE:7096) Forward Dividend Yield %: 0.00% (As of Jul. 13, 2026)


TSE:7096 StemCell Institute TSE:7096
69 GF Score
Price 円768.00
GF Value 円1,813.82
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is StemCell Institute Forward Dividend Yield %?

StemCell Institute TSE:7096 +0.92% 69 Forward Dividend Yield % is 0.00% as of Jul. 13, 2026. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.82 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 148 Biotechnology companies, StemCell Institute ranks worse than 675675% on this metric.

As of today (2026-07-13), the Forward Annual Dividend Yield of StemCell Institute is 0.00%.

As of today (2026-07-13), the Trailing Annual Dividend Yield of StemCell Institute is 0.00%.

TSE:7096's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.275
* Ranked among companies with meaningful Forward Dividend Yield % only.

StemCell Institute's Dividends per Share for the six months ended in Mar. 2026 was 円0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


StemCell Institute  (TSE:7096) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


StemCell Institute Forward Dividend Yield % Related Terms


TSE:7096 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, StemCell Institute's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemCell Institute Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCell Institute's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where StemCell Institute's Forward Dividend Yield % falls into.


TSE:7096
69GF Score
StemCell Institute TSE:7096
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCell Institute Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
StemCell Institute (TSE:7096) has a Forward Dividend Yield % of 0.00% as of Jul. 13, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on StemCell Institute and its competitors. According to the industry distribution chart, StemCell Institute ranks #999999 out of 148 companies in the Biotechnology industry.
Is StemCell Institute's Forward Dividend Yield % too high?
StemCell Institute's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, StemCell Institute ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #999999 out of 148 companies for Forward Dividend Yield %. This places StemCell Institute in the lower half of its industry. The industry median Forward Dividend Yield % is 1.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.28, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.82, compared to a current price of 円768.00 — trading 57.7% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Forward Dividend Yield % is 0.00% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円768.00 is trading 57.7% below its estimated GF Value™ of 円1,813.82. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

  • Forward Dividend Yield %: 0.00%
  • GF Value™: 円1,813.82 vs. price of 円768.00 (57.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


StemCell Institute Business Description

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score

Get the complete analysis for TSE:7096

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円768.00
Price
円1,813.82
GF Value